Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Direxion Daily S&P 500 Bull 3X Shares (SPXL) vs Tempus AI (TEM) Price & Performance

Direxion Daily S&P 500 Bull 3X SharesTrade

Price performance (Past 24H)

Key statistics

Direxion Daily S&P 500 Bull 3X Shares vs Tempus AI — how do they compare? Direxion Daily S&P 500 Bull 3X Shares trades at $296.4, while Tempus AI trades at $54.24 (market cap $10.05B). The key difference: Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals.

SPXLTEM
Sector
Leveraged / InverseBroad Market / Factor
52-Week High
$296.39$103.25
52-Week Low
$170.20$41.55
Market Cap
$10.05B
Enterprise Value
$10.68B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Direxion Daily S&P 500 Bull 3X Shares

SPXL, a leveraged ETF tracking the S&P 500, trades at $295.99, down 0.07% on the day, with technical indicators showing a bullish moving average trend but overbought RSI signals. The ETF reflects the S&P 500's record highs, driven by strong corporate earnings and AI optimism, though valuation concerns persist. Recent news highlights mixed sentiment, with JPMorgan raising its S&P 500 target to 8,000 while some warn of overvaluation risks.

The outlook for SPXL hinges on S&P 500 performance, offering amplified gains in a bullish market but heightened losses in downturns. Key opportunities include continued AI-driven earnings growth, while risks involve market volatility, inflation reports, and potential pullbacks from elevated levels. Investors should weigh leverage effects against broader index trends.

Tempus AI

Tempus AI (TEM) trades at $54.48, down 1.05% today, with a bullish technical signal from moving averages but overbought RSI levels. The company reported a Q2 2026 loss of $0.04 per share, beating estimates, and raised 2026 revenue guidance to $1.4 billion. Recent news highlights growth in oncology testing and AI-driven precision medicine, including the planned acquisition of Personalis to expand minimal residual disease testing capabilities.

Outlook remains positive with 61.5% analyst buy ratings and a $61.57 consensus price target, though risks include persistent net losses, high cash burn from operations, and competitive pressures in AI healthcare. The stock offers upside if execution improves profitability, but investors should monitor cash flow sustainability and integration of acquisitions.

Returns comparison

Trailing returns across standard periods

About Direxion Daily S&P 500 Bull 3X Shares

SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.

Read more on SPXL

About Tempus AI

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

Read more on TEM